The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is often caused by sarcomere gene mutations, resulting in left ventricular hypertrophy (LVH), myocardial fibrosis, and increased risk of sudden cardiac death and heart failure. Studies in mouse models of sarcomeric HCM demonstrated that early treatment w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am Heart J
Main Authors: Ho, Carolyn Y., McMurray, John J. V., Cirino, Allison L., Colan, Steven D., Day, Sharlene M., Desai, Akshay S., Lipshultz, Steven E., MacRae, Calum A., Shi, Ling, Solomon, Scott D., Orav, E. John, Braunwald, Eugene
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5586211/
https://ncbi.nlm.nih.gov/pubmed/28454798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ahj.2017.02.008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados